P1.17.29 Access to Novel Therapies for the Treatment of NSCLC in 18 EU Member States
Janzic U, Illini O, Zlatanova T, Arabadjiev J, Jakopovic M, Fotopoulos G, Valter A, Saalfeld FC, Wermke M, Charpidou A, Naidoo J, Reilly DO, Novello S, Bironzo P, Gedvilaite V, Berchem G, Pluzanski A, Braga MM, Araújo A, Ivancík J, Katona Z, Gorria T, Mezquita L, Hofmarcher T, Debakker S, Hendriks L.
Swift advancement in anticancer drug development in the last two decades for the treatment of NSCLC (non-small cell lung cancer) patients poses challenges in availability of these therapies in EU countries. Although EU countries share the same regulatory status through the EMA, access to anticancer treatments vary significantly.
Journal of Thoracic Oncology, 2025;20(10):S223-S224
DOI: https://doi.org/10.1016/j.jtho.2025.09.414
